Compare AMRC & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMRC | LXRX |
|---|---|---|
| Founded | 2000 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 990.6M |
| IPO Year | 2010 | 2000 |
| Metric | AMRC | LXRX |
|---|---|---|
| Price | $25.65 | $2.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 2 |
| Target Price | ★ $37.88 | $4.15 |
| AVG Volume (30 Days) | 640.3K | ★ 2.7M |
| Earning Date | 05-04-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 77.78 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,769,928,000.00 | $49,803,000.00 |
| Revenue This Year | $10.71 | N/A |
| Revenue Next Year | $9.07 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 60.24 |
| 52 Week Low | $18.38 | $1.02 |
| 52 Week High | $44.93 | $2.68 |
| Indicator | AMRC | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 54.05 | 53.30 |
| Support Level | $24.73 | $2.08 |
| Resistance Level | $33.03 | $2.56 |
| Average True Range (ATR) | 1.86 | 0.18 |
| MACD | 0.71 | 0.00 |
| Stochastic Oscillator | 52.93 | 71.43 |
Ameresco Inc is an energy infrastructure solutions provider dedicated to helping customers reduce costs, enhance resilience, and decarbonize to net zero in the energy transition. Its comprehensive portfolio includes implementing smart energy efficiency solutions, upgrading aging infrastructure, and developing, constructing, and operating distributed energy resources. Its solutions range from upgrades to facility's energy infrastructure to the development, construction and operation of renewable energy plants combined with tailored financial solutions. Its segments include North America Regions, U.S. Federal, Renewable Fuels, Europe, and Others. The majority of the revenue is derived from North America Regions segment.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.